NDA 022468 · Acrotech Biopharma
Folotyn
Pralatrexate · Intravenous · Folate Analog Metabolic Inhibitor
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Sep 24, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
42
6 Phase 3, 7 recruiting
FAERS reports
650
603 serious, 164 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 16, 2026.
FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [ see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). FOLOTYN is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 24, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
2 products under this application
- FOLOTYN · PRALATREXATE 20MG/ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- FOLOTYN · PRALATREXATE 40MG/2ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Pralatrexate" as an intervention, any sponsor and status, largest first.
- To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLPivotal-lookingActive, not recruiting
Acrotech Biopharma Inc.Industry
NCT06072131 · 504 participants (planned) · Start Oct 4, 2023 · Primary completion Jul 2030
Drug: Belinostat Injection; Pralatrexate Injection and 2 more · For: Peripheral T Cell Lymphoma
Sites: Clovis, California; Santa Monica, California; Aurora, Colorado · 58 sites in all
- Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01482962 · 271 participants · Start Jun 11, 2012 · Primary completion Jun 30, 2015
Drug: Alisertib; Pralatrexate and 2 more · For: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
Sites: Birmingham, Alabama; La Jolla, California; Orlando, Florida · 151 sites in all
- Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based TreatmentPivotal-lookingCompleted
Spectrum Pharmaceuticals, IncIndustry
NCT00606502 · 201 participants · Start Jan 2008 · Primary completion Jun 24, 2010
Drug: Pralatrexate; Erlotinib · For: Non-small Cell Lung Cancer
Sites: Bakersfield, California; San Diego, California; Port Saint Lucie, Florida · 47 sites in all
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaPivotal-lookingRecruiting
Corvus Pharmaceuticals, Inc.Industry
NCT06561048 · 150 participants (planned) · Start Oct 2, 2024 · Primary completion Nov 2027
Drug: Soquelitinib; Belinostat and 1 more · For: Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma and 4 more
Sites: Duarte, California; Irvine, California; San Francisco, California · 37 sites in all
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaPivotal-lookingRecruiting
University of VirginiaAcademic, hospital or other
NCT03161223 · 148 participants (planned) · Start May 30, 2018 · Primary completion Feb 2023
Drug: Durvalumab; Pralatrexate and 2 more · For: Lymphoma, T-Cell
Sites: Charlottesville, Virginia
- Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative MalignanciesPivotal-lookingCompleted
Acrotech Biopharma Inc.Industry
NCT00481871 · 119 participants · Start May 2007 · Primary completion May 2011
Drug: Pralatrexate Injection; Gemcitabine Hydrochloride · For: Relapsed or Refractory Lymphoproliferative Malignancies; Hodgkin's Lymphoma; Peripheral T-cell Lymphoma and 2 more
Sites: Los Angeles, California; Stanford, California; Denver, Colorado · 15 sites in all
Acrotech Biopharma Inc.Industry
NCT00364923 · 115 participants · Start Aug 2006 · Primary completion Jan 2009
Drug: Pralatrexate Injection · For: Peripheral T-cell Lymphoma
Sites: Duarte, California; Los Angeles, California; New Haven, Connecticut · 32 sites in all
- A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCLPivotal-lookingCompleted
Mundipharma (China) Pharmaceutical Co. LtdIndustry
NCT03349333 · 85 participants · Start Sep 10, 2015 · Primary completion Jul 21, 2017
Drug: pralatrexate · For: Refractory Peripheral T-Cell Lymphoma; Relapsed T-Cell Lymphoma
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression118
- stomatitis103
- disease progression71
- mucosal inflammation64
- platelet count decreased57
- pyrexia51
- anaemia49
- neutrophil count decreased42
- drug ineffective41
- febrile neutropenia39
- neutropenia34
- off label use33
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 31 |
| 2011 | 33 |
| 2012 | 38 |
| 2013 | 37 |
| 2014 | 15 |
| 2015 | 24 |
| 2016 | 29 |
| 2017 | 24 |
| 2018 | 46 |
| 2019 | 43 |
| 2020 | 62 |
| 2021 | 105 |
| 2022 | 59 |
| 2023 | 35 |
| 2024 | 24 |
| 2025 | 33 |
| 2026 | 12 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Folotyn* (Pralatrexate*) · HCPCS J9307
2024 spending
$21.3M
Beneficiaries
137
1,459 claims
Per beneficiary
$155,281
2024 ASP limit $315.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $21,673,585 |
| 2021 | $21,749,113 |
| 2022 | $20,225,398 |
| 2023 | $23,008,391 |
| 2024 | $21,273,530 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, et al. · J Clin Oncol 2011 · Clinical Trial, Phase II, Multicenter Study
- Pralatrexate pharmacology and clinical development.
Marchi E, Mangone M, Zullo K, et al. · Clin Cancer Res 2013 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial.
Iyer SP, Johnston PB, Barta SK · Blood Adv 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.
Malik SM, Liu K, Qiang X, et al. · Clin Cancer Res 2010 · Clinical Trial, Phase II, Multicenter Study
- Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
Hong X, Song Y, Huang H, et al. · Target Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
- Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.
Stewart JR, Desai N, Rizvi S, et al. · Eur J Dermatol 2018 · Comparative Study, Systematic Review
Sponsor: Acrotech Biopharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.